BPTH Bio-Path Holdings Inc.

0.40
+0.01  (4%)
Previous Close 0.38
Open 0.38
Price To book 4.39
Market Cap 39522510
Shares 100,056,988
Volume 111,458
Short Ratio 7.73
Av. Daily Volume 379,065

SEC filingsSee all SEC filings

  1. 8-K - Current report 171070206
  2. 8-K - Current report 171066965
  3. 8-K - Current report 171036355
  4. 8-K - Current report 171019708
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017909

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted August 2017 that preparations are being made to enter the safety segment of a Phase 2 clinical trial.
Prexigebersen
Chronic myelogenous leukemia (CML)
Phase 2 first patient enrolled November 2016. Interim analysis due by the end of 2017.
BP-1001
Acute myeloid leukemia (AML)

SEC Filings

  1. 8-K - Current report 171070206
  2. 8-K - Current report 171066965
  3. 8-K - Current report 171036355
  4. 8-K - Current report 171019708
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017909
  6. 8-K - Current report 17974541
  7. 8-K - Current report 17968516
  8. 8-K - Current report 17919912
  9. 8-K - Current report 17919174
  10. 8-K - Current report 17897418